AD was present in 44.5% (251/563). EO-C-AD was present in 26.2% of AD (66/251). In the AD sample, univariate logistic regression of EO-C-AD vs BP-II, index age, female gender, recurrences, axis I ...

This statement summarizes the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations regarding CYP450 genetic testing in adult patients beginning treatment ...

A new U.S. Department of Veterans Affairs study found that pharmacogenomic testing can help providers avoid prescribing antidepressant medications that may have undesirable outcomes. Pharmacogenomics ...

Pharmacogenetic testing was associated with nearly a two-fold (89 per cent) increase in remission rates compared to treatment as usual in a Centre for Addiction and Mental Health- (CAMH-)led clinical ...

Acquisitions, partnerships, and collaborations were among the market’s inorganic growth strategies. As a result of these activities, Europe Pharmacogenetics Testing in Psychiatry/Depression market ...

Personalized medicine is the unique tailoring of medical treatment to a patient’s individual symptoms AND their genetic profiles. What was once thought of as science fiction is no longer a fantasy - ...

Combinatorial pharmacogenetics-guided treatment did not demonstrate improved outcomes compared to treatment-as-usual in adolescents with depression, and future research should examine specific ...

Please provide your email address to receive an email when new articles are posted on . COVID-19 has caused major physical and psychological harm for millions of ...

Pharmacogenetic testing was associated with nearly a two-fold (89 per cent) increase in remission rates compared to treatment as usual in a recent clinical study. Pharmacogenetic testing was ...

Depression is diagnosed by tracking at least five persistent symptoms for two weeks. A doctor will use interviews and questionnaires to diagnose you with depression. You may be screened for anemia or ...